Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Lenvatinib in Metastatic Differentiated Thyroid Cancer
NCT03139747Phase 2Suspended
- Sponsor
- Thomas Jefferson University
- Start
- Apr 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of everolimus in differentiated thyroid cancer (DTC), sponsored by Thomas Jefferson University. Started Apr 2017; status: suspended.
02
Drugs
everolimus
03
Conditions
differentiated thyroid cancer (DTC)
Beyond the preview
Go deeper on NCT03139747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03139747.